Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Reiberger

Showing results (411-420 of 491) with videos related to

Pageof 50
Sort By:
Iscience|March 12, 2024
Transcriptomic signatures of progressive and regressive liver fibrosis and portal hypertensionOleksandr Petrenko, Philipp Königshofer, Ksenia Brusilovskaya, et al.
The Lancet. Gastroenterology & Hepatology|July 21, 2023
Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysisElton Dajti, Federico Ravaioli, Romanas Zykus, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 13, 2022
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver diseaseBenedikt Simbrunner, Ida Falk Villesen, Philipp Königshofer, et al.
Ultraschall in Der Medizin (Stuttgart, Germany : 1980)|August 7, 2025
UDFF and Auto pSWE accurately assess liver steatosis and fibrosis risk in obese patients with MASLDNina Dominik, Larissa Nixdorf, Michael Schwarz, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 16, 2021
Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patientsCaroline Schmidbauer, David Chromy, Victor U Schmidbauer, et al.
JHEP Reports : Innovation in Hepatology|February 12, 2026
Treatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis DLisa Sandmann, Mathias Jachs, Tammo L Tergast, et al.
Scientific Reports|July 30, 2024
Rapid improvement of hepatic steatosis and liver stiffness after metabolic/bariatric surgery: a prospective studyLarissa Nixdorf, Lukas Hartl, Stefanie Ströhl, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 16, 2025
Insulin-like Growth Factor-1 Reflects Liver Disease Stage and Improves Prediction of Liver-related MortalityCarolin V Schneider, Stefan Gross, Sriram Balasubramani, et al.
JHEP Reports : Innovation in Hepatology|June 17, 2025
Minimal residual ascites 3 months after TIPS implantation implicates worse clinical outcomes in patients with cirrhosisJim Benjamin Mauz, Lukas Hartl, Andrea Kornfehl, et al.
Journal of Hepatology|December 21, 2016
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunctionPhilipp Schwabl, Eva Hambruch, Berit A Seeland, et al.
Pageof 50

Showing results (411-420 of 491) with videos related to

Sort By:
Pageof 50
Iscience|March 12, 2024
Transcriptomic signatures of progressive and regressive liver fibrosis and portal hypertensionOleksandr Petrenko, Philipp Königshofer, Ksenia Brusilovskaya, et al.
The Lancet. Gastroenterology & Hepatology|July 21, 2023
Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysisElton Dajti, Federico Ravaioli, Romanas Zykus, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 13, 2022
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver diseaseBenedikt Simbrunner, Ida Falk Villesen, Philipp Königshofer, et al.
Ultraschall in Der Medizin (Stuttgart, Germany : 1980)|August 7, 2025
UDFF and Auto pSWE accurately assess liver steatosis and fibrosis risk in obese patients with MASLDNina Dominik, Larissa Nixdorf, Michael Schwarz, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 16, 2021
Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patientsCaroline Schmidbauer, David Chromy, Victor U Schmidbauer, et al.
JHEP Reports : Innovation in Hepatology|February 12, 2026
Treatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis DLisa Sandmann, Mathias Jachs, Tammo L Tergast, et al.
Scientific Reports|July 30, 2024
Rapid improvement of hepatic steatosis and liver stiffness after metabolic/bariatric surgery: a prospective studyLarissa Nixdorf, Lukas Hartl, Stefanie Ströhl, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 16, 2025
Insulin-like Growth Factor-1 Reflects Liver Disease Stage and Improves Prediction of Liver-related MortalityCarolin V Schneider, Stefan Gross, Sriram Balasubramani, et al.
JHEP Reports : Innovation in Hepatology|June 17, 2025
Minimal residual ascites 3 months after TIPS implantation implicates worse clinical outcomes in patients with cirrhosisJim Benjamin Mauz, Lukas Hartl, Andrea Kornfehl, et al.
Journal of Hepatology|December 21, 2016
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunctionPhilipp Schwabl, Eva Hambruch, Berit A Seeland, et al.
Pageof 50